Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$12.87 USD
-0.53 (-3.96%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $13.15 +0.28 (2.18%) 7:06 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.87 USD
-0.53 (-3.96%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $13.15 +0.28 (2.18%) 7:06 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Zacks News
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why You Should Invest in Avadel (AVDL) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
by Zacks Equity Research
The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
by Zacks Equity Research
Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.
Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.
Implied Volatility Surging for Avadel (AVDL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.
Avadel (AVDL) Surges: Stock Moves 7.8% Higher
by Zacks Equity Research
Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
How Avadel (AVDL) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
by Zacks Equity Research
On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.
Avadel's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.
Is Avadel Pharmaceuticals (AVDL) Stock a Solid Choice Right Now?
by Zacks Equity Research
Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
by Zacks Equity Research
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
Avadel (AVDL) Is Up 21.13% in One Week: What You Should Know
by Zacks Equity Research
Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Top-Ranked ADRs That More Than Doubled the S&P 500 in 2019
by Sanghamitra Saha
Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.